Analysis of a New High Throughput Screening Detection Technology for Rapid hERG Safety Testing Using a Fluorescence Polarization Assay

The vast majority of drugs associated with acquired QT prolongation are known to interact with hERG. In this application note from BioTek, the use if the Synergy™ Neo HTS detection platform for hERG screening via a fluorescence polarization based assay is described. Using assay controls and a panel of multiple hERG inhibitors, analysis of pharmacology endpoints for instrument validation include Z’, assay window, precision and plate read times. Additionally, FP-based IC₅₀ data is generated and compared to data from traditional electrophysiological and radiometric methods.